MedTrace Logo

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

NCT01056874 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2011-04-07

No results posted yet for this study

Summary

This is an open labelled study to estimate the effect of maraviroc on the pharmacokinetics of digoxin, a probe for p-glycoprotein.

Conditions

  • Healthy
  • HIV Infections

Interventions

DRUG

Digoxin

Oral Digoxin 0.25 mg single dose

DRUG

Digoxin

Oral Digoxin 0.25 mg single dose on Day 5

DRUG

Maraviroc

Oral Maraviroc 300 mg twice daily for 6 days

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01056874 on ClinicalTrials.gov